Terazosina [Inn-Spanish] en es it fr

Terazosina [Inn-Spanish] Brand names, Terazosina [Inn-Spanish] Analogs

Terazosina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Terazosina [Inn-Spanish] Chemical_Formula


Terazosina [Inn-Spanish] RX_link


Terazosina [Inn-Spanish] fda sheet

Terazosina_[Inn-Spanish] FDA

Terazosina [Inn-Spanish] msds (material safety sheet)

Terazosina [Inn-Spanish] Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Terazosina [Inn-Spanish] Molecular Weight

387.433 g/mol

Terazosina [Inn-Spanish] Melting Point

273 oC

Terazosina [Inn-Spanish] H2O Solubility


Terazosina [Inn-Spanish] State


Terazosina [Inn-Spanish] LogP


Terazosina [Inn-Spanish] Dosage Forms


Terazosina [Inn-Spanish] Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Terazosina [Inn-Spanish] Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Terazosina [Inn-Spanish] Absorption

Essentially completely absorbed in man (90% bioavailability).

Terazosina [Inn-Spanish] side effects and Toxicity

LD50=259.3mg/kg (i.v. in mice)

Terazosina [Inn-Spanish] Patient Information

Terazosina [Inn-Spanish] Organisms Affected

Humans and other mammals